Trametinib, a MEK1/2 Inhibitor, Protects Mice from Cisplatin- and Noise-Induced Hearing Loss

Richard D. Lutze(Creighton University), Tal Teitz(St. Jude Children's Research Hospital)
Pharmaceuticals
June 5, 2024
10.3390/ph17060735
Cited by 3

Related Papers

CDK2 inhibitors as candidate therapeutics for cisplatin- and noise-induced hearing loss
|The Journal of Experimental Medicine|2018|102
Preclinical Models for Neuroblastoma: Establishing a Baseline for Treatment
|PLoS ONE|2011|97
Oseltamivir (Tamiflu), a Commonly Prescribed Antiviral Drug, Mitigates Hearing Loss in Mice
|bioRxiv (Cold Spring Harbor Laboratory)|2024|1
FDA-Approved MEK1/2 Inhibitor, Trametinib, Protects Mice from Cisplatin and Noise-Induced Hearing Loss
|bioRxiv (Cold Spring Harbor Laboratory)|2024|0